Long-Lasting Dysregulation of the Hematopoietic Stem Cell Compartment in Obesity

Blood ◽  
2015 ◽  
Vol 126 (23) ◽  
pp. 245-245
Author(s):  
Jung-Mi Lee ◽  
Bryan Goddard ◽  
Ashwini S. Hinge ◽  
Bruce J. Aronow ◽  
Nathan Salomonis ◽  
...  

Abstract Obesity is a complex pathological state defined by the excessive accumulation of adipose tissue and an array of hormonal, immunological and metabolic dysregulations. As such, obesity is a systemic stress that directly affects numerous organs and tissues. Notably, obesity and its sequelae modulate the immune system and the hematopoietic activity in the bone marrow (BM). Not surprisingly, obesity is also a well-established risk factor for leukemia associated with increased incidence and poor prognosis. However, despite their clinical relevance, mechanisms by which obesity affects the hematopoietic system remain elusive. Particularly, the impact of obesity on the hematopoietic stem cell (HSC) compartment has not been described. Using genetic and dietary mouse models of obesity, we conducted a "HSC-centered study" to determine how obesity affects HSCs and how these cells develop specific compensatory mechanisms to respond to this environment. Although HSCs in an obese environment displayed limited phenotypic and functional perturbations at steady state, they showed an aberrant response to hematopoietic stresses. In serial competitive transplantation assays, obesity-primed HSCs (defined as Lin- Sca-1+ c-Kit+ CD48- CD150+) showed a higher level of engraftment than controls in primary recipient mice (control, 20.8% +/-6.2 vs obese, 45.5% +/-14.6, p=0.022) but a dramatically reduced level of engraftment in secondary recipient mice (control: 25.8% +/-14.0 vs obese: 5.4% +/-3.9, p=0.033). Interestingly, BM analysis of secondary recipients showed reduced chimerism in all hematopoietic compartments but not in the HSC compartment. Altogether these results uncovered a biphasic behavior of the obesity-primed HSCs, characterized by an excessive differentiation response followed by a functional decline in which HSCs self-renew but fail to produce downstream progenitors. To unveil the molecular mechanisms involved in this aberrant activity, we performed a genome-wide gene expression analysis on HSCs isolated from normal and obese mice. Although the phenotype observed upon serial transplantation partially mimics HSC aging, obesity-primed HSCs did not share the molecular signature of old HSCs. Furthermore, down-regulation of interferon response-related genes (e.g Irak4, Irf7, Ifi27) and stress response-related genes (e.g. Stip1, Cgrrf1) showed that, unlike what has been described for committed progenitors, HSCs do not elicit a dramatic response to the inflammatory environment associated with obesity. In contrast obesity leads to the activation of specific molecular programs in HSCs. Firstly, obesity-primed HSCs showed up-regulation of multiples genes involved in the phosphatidylinositol signaling pathway (e.g. Pi4ka, Pi4k2b, Pi3kap1, Pi3kip1). Phosphoflow cytometry analysis indicated that this gene expression pattern was associated with the constitutive activation of the protein kinase AKT. While AKT activation is linked to functional HSC exhaustion, obesity-primed HSCs appeared refractory to this signal, suggesting the existence of compensatory mechanisms that protect the integrity of the HSCs in an obese environment. In parallel, we found that the aberrant activity of the obesity-primed HSCs was correlated with an elevated expression of Gfi1, a transcription factor critical for HSC quiescence and differentiation. Interestingly, the 2-fold increase in Gfi1 expression (p<10-5) observed in obesity-primed HSCs was maintained after serial transplantations in normal recipient mice indicating that the obese environment was able to promote the selection of a stable molecular program in the HSC compartment. Consistent with this idea, single-cell genome-wide analyses suggested a significant clonal shift within the obesity-primed HSC compartment. Finally, consistent with epidemiological data, we found that disruption of HSC homeostasis by obesity promotes the development of spontaneous hematopoietic pathologies resembling to myeloproliferative diseases. Altogether, our results establish the long lasting impact of obesity on the HSC compartment and uncover potential molecular mechanisms linking obesity to hematological diseases. Notably our results support the intriguing possibility that obesity, by directly acting on the HSC compartment, contributes to the development of a clonal hematopoiesis and favors the emergence of aberrant HSC clones. Disclosures No relevant conflicts of interest to declare.

Blood ◽  
2019 ◽  
Vol 134 (Supplement_1) ◽  
pp. 4557-4557
Author(s):  
Wei Wang ◽  
Paul Auer ◽  
Stephen R. Spellman ◽  
Karen-Sue B. Carlson ◽  
Aziz Nazha ◽  
...  

Myelodysplastic syndromes (MDS) are a heterogeneous group of hematopoietic stem cell disorders for which allogeneic hematopoietic stem cell transplantation (HCT) is currently the only curative treatment. Epigenetic lesions are considered a major pathogenetic determinant in many cancers, including MDS, and combination epigenetic therapies have emerged. In this study, we hypothesize that interplay between key epigenomic signatures in the MDS patient undergoing HCT and their donor epigenomic profile serve as a prognostic factor of post-HCT MDS relapse risk. Reduced representation bisulfite sequencing (RRBS) was chosen to identify genome-wide epigenetic alterations as a cost-efficient method for building large data resources that reduces sequence redundancy and selects only CpG-rich regions of the genome for sequencing. A unique cohort of 188 samples from the Center for International Blood and Marrow Transplant Research (CIBMTR) biorepository was sequenced through RRBS. This cohort was composed of 94 pre-transplant samples from MDS patients that received peripheral blood stem cell grafts and were selected as case/controls for post-HCT relapse/non-relapse matched on patient, disease and transplant characteristics. The remaining 94 samples were from the patients' healthy allogeneic donors. Only patient samples that were wild-type for previously-identified MDS-prognostic TP53, RAS pathway and JAK2 mutations were included in this cohort to promote discovery of novel factors. We developed methylPrep, a Python application, to filter the low methylation calls and group shared sites by donors, relapsed patients and non-relapsed patients. We comprehensively identified differentially methylated regions (DMRs) by comparing the methylation patterns in healthy donors and MDS patients that relapsed or did not relapse. The healthy donor group displayed higher global methylation levels (GML) than the patient group as a whole, and the relapsed patient showed higher GML than the non-relapsed patient, though these differences were not statistically significant, and we continue to investigate whether hypo-methylating agents play a role. We selected high DMRs (50-bp interval), with at least 25% difference in methylation calls, using Fisher's exact test, where the threshold q-value equals 0.05, and uncovered 367 significant hyper-DMRs and 38 significant hypo-DMRs in donors compared to patients genome-wide. For disease relapsed versus non-relapsed MDS patients, we identified 121 hyper-DMRs and 64 hypo-DMRs, and the distribution of DMRs was highly varied. Furthermore, we compared epigenome compatibility between donors and patients who did or did not relapse after transplantation and discovered a distinct difference in DMR patterns from chromosome to chromosome and through region annotation. Interestingly, a higher number of DMRs were located in promoter regions between donors and non-relapsed patients versus donors and disease-relapsed patients. Identified DMRs, especially those located in promoter regions, may be involved in regulation of gene expression. These promoter DMRs may serve as candidate indicators or sites for potential diagnosis and therapy selection for MDS patients and may aid in the prediction of transplant outcomes and matching of the best donor for the MDS patient. Continued investigation will enable validation and assessment of the impact and mode of action for these distinct methylation signatures and global methylation patterns in MDS associated with HCT outcomes. Figure Disclosures Nazha: Incyte: Speakers Bureau; Daiichi Sankyo: Consultancy; Jazz Pharmacutical: Research Funding; Novartis: Speakers Bureau; Tolero, Karyopharma: Honoraria; MEI: Other: Data monitoring Committee; Abbvie: Consultancy.


2021 ◽  
Vol 10 (5) ◽  
pp. 1113
Author(s):  
Kinga Musiał ◽  
Krzysztof Kałwak ◽  
Danuta Zwolińska

Background: Knowledge about the impact of allogeneic hematopoietic stem cell transplantation (alloHSCT) on renal function in children is still limited. Objectives: The aim of the study was to evaluate kidney function in children undergoing alloHSCT, with special focus on differences between patients transplanted due to oncological and non-oncological indications. Materials and Methods: The data of 135 children undergoing alloHSCT were analyzed retrospectively. The serum creatinine and estimated glomerular filtration rate (eGFR) values were estimated before transplantation at 24 h; 1, 2, 3, 4 and 8 weeks; and 3 and 6 months after alloHSCT. Then, acute kidney injury (AKI) incidence was assessed. Results: Oncological children presented with higher eGFR values and more frequent hyperfiltration rates than non-oncological children before alloHSCT and until the 4th week after transplantation. The eGFR levels rose significantly after alloHSCT, returned to pre-transplant records after 2–3 weeks, and decreased gradually until the 6th month. AKI incidence was comparable in oncological and non-oncological patients. Conclusions: Children undergoing alloHSCT due to oncological and non-oncological reasons demonstrate the same risk of AKI, but oncological patients may be more prone to sustained renal injury. Serum creatinine and eGFR seem to be insufficient tools to assess kidney function in the early post-alloHSCT period, when hyperfiltration prevails, yet they reveal significant differences in long-term observation.


Blood ◽  
2004 ◽  
Vol 103 (6) ◽  
pp. 2003-2008 ◽  
Author(s):  
Michael Boeckh ◽  
W. Garrett Nichols

AbstractIn the current era of effective prophylactic and preemptive therapy, cytomegalovirus (CMV) is now a rare cause of early mortality after hematopoietic stem cell transplantation (HSCT). However, the ultimate goal of completely eliminating the impact of CMV on survival remains elusive. Although the direct effects of CMV (ie, CMV pneumonia) have been largely eliminated, several recent cohort studies show that CMV-seropositive transplant recipients and seronegative recipients of a positive graft appear to have a persistent mortality disadvantage when compared with seronegative recipients with a seronegative donor. Recipients of T-cell–depleted allografts and/or transplants from unrelated or HLA-mismatched donors seem to be predominantly affected. Reasons likely include both incomplete prevention of direct and indirect or immunomodulatory effects of CMV as well as consequences of drug toxicities. The effect of donor CMV serostatus on outcome remains controversial. Large multicenter cohort studies are needed to better define the subgroups of seropositive patients that may benefit from intensified prevention strategies and to define the impact of CMV donor serostatus in the era of high-resolution HLA matching. Prevention strategies may require targeting both the direct and indirect effects of CMV infection by immunologic or antiviral drug strategies.


2013 ◽  
Vol 6 (S1) ◽  
Author(s):  
Annarita Miccio ◽  
Clelia Peano ◽  
Oriana Romano ◽  
Guidantonio Tagliazucchi ◽  
Luca Petiti ◽  
...  

2020 ◽  
Vol 55 (10) ◽  
pp. 2043-2044 ◽  
Author(s):  
Jeff Szer ◽  
Daniel Weisdorf ◽  
Sergio Querol ◽  
Lydia Foeken ◽  
Alejandro Madrigal

Sign in / Sign up

Export Citation Format

Share Document